About this event
Every protein production campaign—whether for research or drug discovery—starts with the same uncertainty: Will this construct express? Will it purify? Should we use bacterial or eukaryotic systems?
With an influx of computationally designed constructs and the need to screen multiple variants, answering these questions traditionally takes weeks of trial and error.
Join Dr. Magdalena Richter, Associate Principal Scientist at AstraZeneca, as she details how her team systematically addressed this bottleneck. By benchmarking Nuclera’s eProtein Discovery™ system against standard E. coli cell-based expression, her team asked a critical question: Can a 24-hour, cell-free screen accurately predict expression success at scale?
Dr. Richter will share the benchmarking data demonstrating strong translatability between the two platforms. Discover how Dr. Richter is using this data to build a robust "screen-to-protein in one week" workflow, rapidly triaging constructs, identifying quick wins, flagging targets requiring alternative expression systems, and feeding actionable feasibility data directly into project planning.
Hosted by
Dr. Magdalena Richter is an Associate Principal Scientist at AstraZeneca, Cambridge, where she drives capability development and technology adoption within the Protein Science team to accelerate the delivery of challenging recombinant targets for early discovery. She specializes in the production and characterization of intrinsically disordered proteins, transcription factors, and protein complexes, leading the integration of new platform technologies into established protein science workflows. Dr. Richter partnered with Nuclera during their alpha trial phase and has successfully embedded the eProtein Discovery™ system into AstraZeneca's construct triaging strategy. She trained at the University of Cambridge and the Polish Academy of Sciences.
Nuclera empowers researchers to accelerate discovery with rapid, in-house access to high-quality functional proteins.